Use of polyclonal rabbit antibodies for detection of the bcr-abl fusion zone in cells transfected with experimental bcr-abl DNA vaccines

International Journal of Oncology

Volumn 27, Issue 1, 2005, Pages 265-274

  Ludvikova V ^a   Hamsikova E ^a   Sobotkova E ^a   Lucansky, V ^a   Smahel, M ^a   Vonka, V ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

bcr abl; CML; Rabbit antibodies; Vaccines

Indexed keywords

ANTIBODY; BCR ABL PROTEIN; COMPLEMENTARY DNA; DNA VACCINE; HEAT SHOCK PROTEIN 70; PEPTIDE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CHEMISTRY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOUSE; PLASMID; PROTEIN TERTIARY STRUCTURE; RABBIT; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA, COMPLEMENTARY; FUSION PROTEINS, BCR-ABL; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MICE; MICE, INBRED BALB C; MODELS, GENETIC; PEPTIDES; PLASMIDS; PROTEIN STRUCTURE, TERTIARY; RABBITS; TRANSFECTION; VACCINES, DNA;

EID: 24644478058     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.1.265     Document Type: Article

References (42)

1. Konopka JB and Witte ON: Activation of the abl oncogene in murine and human leukemias. Biochim Biophys Acta 823: 1-17, 1985.
2. Yee K, Anglin P and Keating A: Molecular approaches to the detection and monitoring of chronic myeloid leukemia: theory and practice. Blood Rev 13: 105-126, 1999.
3. Holyoake DT: Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory. Br J Haematol 113: 11-23,2001.
4. Goldman JM and Melo JV: Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 349: 1451-1464,2003.
5. Melo JV and Deininger MW: Biology of chronic myelogenous leukemia - signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 18: 545-568, 2004.
6. Bose S, Deininger M, Gora-Tybor J, Goldman JM and Melo JV: The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92: 3362-3367, 1998.
7. Biernaux C, Loos M, Sels A, Huez G and Stryckmans P: Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86: 3118-3122, 1995.
8. Posthuma EF, Falkenburg JH, Apperley JF, et al: HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 93: 3863-3865, 1999.
9. Chen W, Peace DJ, Rovira DK, You SG and Cheever MA: T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sei USA 89: 1468-1472, 1992.
10. Pawelec G, Max H, Haider T, Bruserud O, Merl A, Da Silva P and Kaibacher H: BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood 88:2118-2124, 1996.
11. Chen X, Regn S, Raffegerst S, Kolb HJ and Roskrow M: Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic Tcell response from patients with chronic myeloid leukaemia. Br J Haematol 111: 596-607, 2000.
12. Vivancos P, Granena A Jr, Sarra J and Granena A: Treatment with interleukin-2 (IL-2) and interferon [IFN(alpha 2b)] after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse. Bone Marrow Transplant 23: 169-172, 1999.
13. Falkenburg JH, Wafelman AR, Joosten P, et al: Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 94: 1201-1208, 1999.
14. Kolb HJ, Schmid C, Chen X, et al: Adoptive immunotherapy in chimeras with donor lymphocytes. Acta Haematol 110: 110-120, 2003.
15. Ten Bosch GJ, Toornvliet AC, Friede T, Melief CJ and Leeksma OC: Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia 9: 1344-1348, 1995.
16. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A and Scheinberg DA: Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 87: 3587-3592, 1996.
17. Yotnda P, Firat H, Garcia-Pons F, et al: Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101: 2290-2296, 1998.
18. Osman Y, Takahashi M, Zheng Z, et al: Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 13: 166-174, 1999.
19. Leeksma OC, Kessler JH, Huijbers IJ, ten Bosch GJ and Melief CJ: BCR-ABL directed immunotherapy: a virtual reality? Leuk Lymphoma 38: 175-181,2000.
20. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al: Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95: 1781-1787, 2000.
21. Norbury LC, Clark RE and Christmas SE: b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol 109: 616-621, 2000.
22. Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB and Scheinberg DA: A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103: 1037-1042, 2004.
23. Mannering SI, McKenzie JL, Fearnley DB and Hart DN: HLADR 1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigenpresenting cells exposed to b3a2 containing cell lysates. Blood 90: 290-297, 1997.
24. Sun JY, Krouse RS, Forman SJ, Senitzer D, Sniecinski I, Chatterjee S and Wong KK Jr: Immunogenicity of a p210(BCRABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Res 62: 3175-3183, 2002.
25. Westermann J, Korner IJ, Kopp J, Kurz S, Zenke M, Dorken B and Pezzutto A: Cryopreservation of mature monocyte-derived human dendritic cells for vaccination: influence on phenotype and functional properties. Cancer Immunol Immunother 52: 194-198,2003.
26. Takahashi T, Tanaka Y, Nieda M, et al: Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res 27: 795-802, 2003.
27. Choudhury A, Gajewski JL, Liang JC, et al: Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89: 1133-1142, 1997.
28. Robinson SP, English N, Jaju R, Kearney L, Knight SC and Reid CD: The in vitro generation of dendritic cells from blast cells in acute leukaemia. Br J Haematol 103: 763-771, 1998.
29. Cignetti A, Bryant E, Allione B, Vitale A, Foa R and Cheever MA: CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 94: 2048-2055, 1999.
30. Heinzinger M, Waller CF, von Den BA, Rosenstiel A and Lange W: Generation of dendritic cells from patients with chronic myelogenous leukemia. Ann Hematol 78: 181-186, 1999.
31. Westermann J, Kopp J, Korner I, et al: Bci7abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia. Bone Marrow Transplant 25 (Suppl 2): 46-49, 2000.
32. He L, Feng H, Raymond A, et al: Dendritic-cell-peptide immunization provides immunoprotection against bcr-ablpositive leukemia in mice. Cancer Immunol Immunother 50: 31-40,2001.
33. Zeng Y, Feng H, Graner MW and Katsanis E: Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 101:4485-4491,2003.
34. Van Denderen J, ten Hacken P, Berendes P, Zegers N, Boersma W, Grosveld G and van Ewijk W: Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias. Leukemia 6: 1107-1112,1992.
35. Daley GQ and Baltimore D: Transformation of an interleukin 3- dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sei USA 85:9312-9316, 1988.
36. McLaughlin J, Chianese E and Witte ON: In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sei USA 84: 6558-6562, 1987.
37. Jinoch P, Zak R, Janouskova O, et al: Immunization with live HPV-16-transformed mouse cells expressing the herpes simplex thymidine kinase and either GM-CSF or IL-2. Int J Oncol 23: 775-783, 2003.
38. Hamsikova E, Novak J, Hofmannova V, et al: Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls. J Infect Dis 170: 1424-1431,1994.
39. Daley GQ, van Etten RA and Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247: 824-830, 1990.
40. Smahel M, Sima P, Ludvikova V and Vonka V: Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 281: 231-238, 2001.
41. Cerovskâ N, Filigarovâ M and Subr Z: Optimization of purification procedure for potato virus Y strain NN. Acta Virol 41: 47-49, 1997.
42. Kingston RE, Chen CA, Okayama H and Rose JK: Calcium phosphate transfection. In: Current Protocols in Molecular Biology. Ausubel FA, Brent R and Kingston RE (eds). John Wiley & Sons, New York, pp9.1.04-9.1.11,1997.